New and promising anti-bacterials: Can this promise be sustained?

Sai Saran, Namrata S. Rao, and Afzal Azim

Department of Critical Care Medicine, Super Speciality Cancer Institute and Hospital, CG City, India
1Department of Nephrology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand, Uttar Pradesh, India
2Department of Critical Care Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh, India

Address for correspondence: Prof. Afzal Azim, Department of Critical Care Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow - 226 014, Uttar Pradesh, India. E-mail: draazim2002@gmail.com

Received 2019 Apr 20; Revised 2019 Jun 30; Accepted 2019 Jul 11.

Copyright: © 2020 Journal of Anaesthesiology Clinical Pharmacology

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Abstract

The World Health Organization (WHO) announced antimicrobial resistance (AMR) as a major threat to public health which requires that new antimicrobials need to be developed faster than ever before. The rapid development of resistance has rendered many promising antibacterials useless in treating critically ill patients. This article discusses new antibacterials, which got Food and Drug Administration (FDA) approval in the last few years, along with their key pharmacokinetic and pharmacodynamic (PK/PD) advantages, added antimicrobial spectrum, indications, strengths and weaknesses of these drugs from an intensivist point of view. A brief mention has been made on antimicrobial peptides (AMPs), bacteriophages and nanoparticles, which are likely to dominate the future of antibacterials. Finally, it must be understood that the battle against AMR can only be won by a combination of innovative therapies, good infection control practices, strong antibiotic stewardship in the hands of informed healthcare workers.

Keywords: Antimicrobial resistance, critically ill, new antibacterials, pharmacodynamics, pharmacokinetics

Introduction

The advent of antibacterials heralded an important victory of mankind against disease and death. The timeline of antibacterials began with Alexander Fleming's serendipitous discovery of penicillin, and was followed by a period of rapid growth (till the 1970s') when streptomycin, sulphonamides, tetracyclines and fluoroquinolones were discovered.[1] Following this golden era, the discovery of newer antibacterials went hand in hand with the emergence of resistance mechanisms. The appearance of resistant strains...
followed the discovery of drugs in quick succession, such as penicillin resistant *Staphylococcus aureus* in 1940 and beta-lactamases isolated in Greece (TEM1,2) in 1948, soon after penicillin had come to clinical use.[1] Figure 1 depicts the discovery of antibacterials along with appearance of resistant strains. The appearance of extended spectrum beta-lactamases (ESBL) which are resistant to penicillin and cephalosporins; metallo-beta-lactamases (MBL) which are resistant to carbapenems, and later followed by Klebsiella pneumoniae carbapenemase (KPC) have threatened the clinical utility of antibacterials against gram negative micro organisms in developing countries.[2] Although methicillin-resistant *Staphylococcus aureus* (MRSA) is a major threat to antimicrobial resistance in developed countries it is of less concern in developing countries where infections due to gram negative bacteria (GNB) predominate.[3] Vancomycin resistant enterococci (VRE) are also an important cause of healthcare associated infections for which treatment options need to be developed.[4] Fewer new antibacterials are being added in the last two decades – from 37 drugs in 1983-93 to 18 drugs in 1993-2003, with a progressive decline thereafter.[5] The present times have witnessed a revival of antimicrobials discovered before the 1970s—fosfomycin, minocycline and polymyxin—which have shown efficacy against the extensively drug resistant microbes (XDR) causing infections in intensive care units.[6] Worsening anti-microbial resistance (AMR) has forced innovative, yet disturbing strategies such as the use of suicidal agents like the double-carbapenem-based therapy in which ertapenem is being used as suicidal drug against KPC producing organisms.[7] Another example of an innovative strategy to counter AMR is stool transplantation (fecal microbiota transplantation) in recurrent *Clostridium difficile* infection.[8] Viruses (bacteriophage therapy),[9] plants (aromatic polyketolides)[10] and nanometals[11] are vying for a future role as antibacterials. AMR has been highlighted as a major threat by World Health Organization (WHO).[12]

This review highlights recent promising antibacterials – drugs which are Food and Drug Administration (FDA) approved after phase 3 randomized double-blinded non-inferiority trials.[13] The article highlights the added antimicrobial spectrum, pharmacokinetic and pharmacodynamic (PK/PD) advantages along with prescribed dosage, indications, strengths and weaknesses of these drugs along with landmark trials from an intensivist point of view [Table 1].

**Antibacterials Against Gram Positive Micro-Organisms**

**Lipoglycopeptides**

Dalbavancin and oritavancin are further modified glycopeptides (vancomycin and teicoplanin) with addition of lipid chain which confers the advantage of extended elimination half time of the drug. These drugs do not require drug concentration monitoring, need to be prescribed only once (or repeat doses weekly) and circumvent problems of drug compliance and prolonged requirement of invasive lines.[14] There is no necessity of dosage adjustment in renal and hepatic failure. These drugs are active against VRE (non-vanA mediated) including daptomycin- resistant species, MRSA (mec A and mec C), and some vancomycin intermediate *Staphylococcus aureus* and heteroresistant species (VISA/hVISA). Dalbavancin was non-inferior to vancomycin and linezolid when used for acute bacterial skin and skin structure infections (ABSSI) as in DISCOVER 1 and DISCOVER 2 studies.[15]

**5th generation cephalosporins**

The mechanism of penicillin resistance in *Staphylococcus aureus* is predominantly by reducing binding affinity to penicillin binding proteins (PBP’s), especially PBP2a.[16] This is circumvented by the new fifth generation cephalosporins, ceftaroline and ceftabiprole with increased binding to PBP2a. When compared to a combination of vancomycin and aztreonam in complicated skin and soft tissue infections, ceftaroline fosamil achieved higher clinical cure and microbiological success rates.[15] Ceftaroline also demonstrated good tolerability and success rates[17] in treating hospital acquired pneumonia. An important limitation of these drugs is their lack of activity on *Enterococcus faecium* (*E. faecium*) and ESBL-E (ESBL producing Enterobacteriaceae).
**Tedizolid**

This oxazolidinone has a number of PK/PD advantages over linezolid such as availability as a lyophilized suspension and et

\[ \frac{1}{2} \] of 12 hours (compared to linezolid et

\[ \frac{1}{2} \] of 5-6 hours), which allows for once daily dosing. Linezolid accounts for around 600 ml volume infusion per day which can be reduced with the lyophilized preparation of this drug.[14] Moreover, mitochondrial toxicity (lactic acidosis) seen with prolonged linezolid therapy and myelosuppresion are less frequently observed. Tedizolid has a lower risk of drug interaction with catecholamines, and precipitating serotonin syndrome due to monoamine oxidase inhibition when compared with linezolid. The enzyme cfr methytransferase accounts for development of resistance to linezolid therapy in MRSA, but does not reduce tedizolid concentrations. This drug has shown promising results in the setting of ABSSI and pneumonia due to MRSA.[18] However, like its predecessor, tedizolid shares the limitation of being bacteriostatic.

**Delafloxacin**

Delafloxacin has been developed by removing a protanatable substituent (anionic fluroquinolone) making it weakly acidic, thereby conferring the drug with enhanced intracellular penetration along with heightened bactericidal activity.[19] Another unique property of delafloxacin is “balanced target enzyme inhibition” – both DNA gyrase (usual target in gram negative bacteria) and topoisomerase IV (usual target in gram positive infections) are equally inhibited, which limits the frequency of spontaneous mutations leading to development of resistance during the therapy. The PK/PD advantages are its major metabolism through glucuronidation, which is less affected in critically ill patients when compared to phase 1 reactions (oxidation, reduction and hydrolysis) and non-renal clearance accounting for 35-50% of drug elimination leading to lesser dose modifications in renal failure. This drug was non-inferior to a combination of vancomycin and aztreonam in ABSSI with fewer adverse effects leading to drug discontinuation.[20]

**Fidaxomicin, Actoxumab and Bezlotoxumab**

Fidaxomicin, a macrocyclic antibiotic has revolutionized the management of *Clostridium difficile* infection (CDI) due to its bactericidal property against *C. difficile*, unlike vancomycin and metronidazole which are bacteriostatic.[13] This drug is 8-10 times more potent than vancomycin with minimal systemic absorption and achieving high colonic concentrations after enteral absorption along with prolonged post antibiotic effect. This drug is active against resistant strains of *C. difficile* (NAP1/BI/027).[21] The Infectious Disease Society of America (IDSA) revised their guideline in 2017 to include fidaxomicin as the first line option in severe CDI and first recurrence, replacing the previous role of metronidazole.[22] Fidaxomicin had better cure rates and lower recurrence, when compared with vancomycin in acute CDI as reported by Louie *et al.*[23] Further advancement in the management of CDI (apart from fecal microbiota transplant) is the development of humanized monoclonal antibodies targeting toxin A (actoxumab) and toxin B (bezlotoxumab) respectively.[24] Bezlotoxumab therapy has shown promising results in reducing recurrence rates, when compared to combination therapy and actoxumab therapy alone, in MODIFY I and MODIFY II trials.[24] This shows that inhibiting the toxin to bind to the cell (toxin B) by bezlotoxumab halts the key step in the pathogenesis of CDI, providing an alternative/bridge to FMT in recurrent CDI. The PK/PD advantage of this antibody is its long t

\[ \frac{1}{2} \] (19 days) leading to single dose of 10 mg/kg intravenous dosage which can prevent recurrence upto 12 weeks.[24]

**Antibacterials against Gram Negative Micro-organisms**

**New betalactam/betalactamase inhibitors (BL-BLI)**

Tazobactam based BL-BLI combinations can inhibit few beta lactamases like 2a, 2b, 2be, 2c, 2e which belong to group 2 in Bush-Jacoby classification or Ambler class A and few class D or group 2 (2d and 2de) enzymes.[25] For efficacy against carbapenem resistant *Pseudomonas aeruginosa* (CRPA),
ceftolozane, a third generation anti-pseudomonal cephalosporin with more potency than other anti-pseudomonal cephalosporins is paired with tazobactam.[26] This drug demonstrates activity against Ambler class C (Amp C) enzymes which are traditionally not inhibited tazobactam combinations, and also shows efficacy in treating infections due to ESBL-E and CRPA.[27] Ceftolozane-tazobactam was non-inferior in treating complicated intra-abdominal infections[28] and complicated urinary tract infections[29] when compared with meropenem and levofloxacin, respectively. The main limitation of this combination is its lack of activity on KPC. This problem has been circumvented by the development of ceftazidime-avibactam combination.[25] Avibactam has higher potency than other BLIs due to its covalent reversible binding property to serine β-lactamases.[26] This drug holds promise in carbapenem resistant Enterobacteriaceae (CRE) infections, albeit with lower activity against CRPA. Ceftazidime-avibactam has also demonstrated activity on few class D (OXA-24,48) enzymes, not seen with previous BL-BLI combinations. This drug was tested in combination with metronidazole in patients with complicated intra-abdominal infections in two non-inferiority studies, RECLAIM 1 and 2, and showed comparable cure rates to meropenem.[30] Similar results have been reported in treating complicated urinary tract infections as well.[31] This BL-BLI may have a role as carbapenem-alternatives in the management of hospital-acquired and ventilator-associated pneumonias, as evaluated in the REPROVE study.[32] The Achilles' heel of this drug is its lack of activity against metallo-beta-lactamases (MBL).

**Carbapenem- betalactamase inhibitors (C-BLI)**

Meropenem-vaborbactam is a new C-BLI which has been evaluated in TANGO trial with piperacillin-tazobactam in c-UTI which has shown promising results.[33] The unique structure of vaborbactam with a boron side chain leads to the formation of covalent adduct formed between serine side of β-lactamase and Boron atom causing destabilization of the KPC enzyme.[25] Inhibition of few class D enzymes (OXA-24,48) and lack of activity against MBL are features that this drug shares with ceftaroline-tazobactam previously discussed. The other C-BLI is imipenem-relebactam, which is yet to be approved by the FDA.

**Antibacterials for Future**

Recently, there has been renewed focus on developing alternative antibacterials with inherently lower risks of resistance. These include antimicrobial peptides (AMPs), bacteriophages and nanoparticles. It is likely that some of these may find active clinical use as future antibacterial therapies.[1]

**Antimicrobial peptides**

Biofilm formation plays an important role in various hospital acquired infections like catheter associated urinary tract infection (CAUTI), VAP and central line associated blood stream infection (CLABSI). “Quorum sensing” is a form of molecular communication in bacteria, which enhances virulence.[34] “Communication molecules” such as acyl-homoserine lactone in gram negative bacteria (GNB) and oligopeptides in gram positive bacteria (GPB) are the targets of these AMPs, respectively.[35] The exact mechanism of action of these AMPs is not yet fully understood although they may have predominant activity on cytoplasmic membrane and intracellular structures. Specifically targeted anti-microbial peptides (STAMPs) are modified AMPs in which the AMP is attached to a flexible linker with target domain that attaches specifically to the pathogen and not to the commensal flora thereby preserving normal gut microbiota. This is an important advantage as the gut microbiome has a proven role in metabolic functions, immune function and homeostasis (Gut-Brain Axis).[36] M8(KH)-20 against Pseudomonas aeruginosa and Streptococcus mutants, Agplectasin against MRSA are the STAMPs currently in phase 1 and 2 level of studies, respectively. Peptides which are developed by post translational modification with introduction of cyclic structures to lanthanionine (a thio-ether aminoacid) are labelled “Lantibiotics”.[37] In general, lantibiotics are active in gram positive infections and have potent in vitro
and in vivo activity. Challenges in developing lantibiotics for clinical use include improving antimicrobial activity and physical parameters such as solubility and protease resistance, while curtailing costs.[38] At present, these preparations are available as topical applications used in dental caries.

**Bacteriophages**

Seeking help from viruses (which are the most abundant microbes on the planet) to fight drug resistant bacteria is seemingly logical, and bacteriophages seem to be well suited for the purpose. Bacteriophages offer advantages like rapidity in killing bacteria, specificity to target pathogen, lower chances for developing resistance, synergistic activity with other antibiotics and lysins, apart from their excellent activity on biofilms.[9] Phage lysins are being developed for specific gram positive pathogens (S. pneumoniae, S. aureus, S. pyogenes) and gram negative bacilli too (P. aeruginosa, A. baumannii, Enterobacteriaceae).[39]

**Nanoparticles**

Silver and metal oxides of copper, zinc and iron of 1-100 nm size have been evaluated and utilized in preventing hospital-acquired infections, especially for their role in biofilm prevention as demonstrated by the role of utilization of silver coated endotracheal tubes in NASCENT trial in preventing VAP.[40] Nanoparticles act through multiple mechanisms like oxidative stress induction (release of reactive oxygen species), inhibition of electron transport chain, damage to DNA and other interactions with bacterial metabolism.[11] Cefiderocol is an application of nanomedicine in which the cephalosporin is hidden inside an iron containing shell (catechol siderophore containing ferric iron), which helps to penetrate the outer membrane of GNB inside which the drug is released as “Trojan Horse”. At present, nanoparticles are being developed for use as coating agents to prevent biofilms and as drug transporters. [11]

Laupland et al., reviewed new and promising antimicrobials just a decade ago and the drugs they enlisted, are all in clinical use now and we are already looking beyond them for newer options due to development of AMR against these drugs.[41] While new drugs might play an important role in infections caused by resistant organisms, we should focus on using existing antimicrobials effectively through stringent implementation of antibiotic stewardship.[42] This requires implementation of core elements of stewardship program along with use of resistance tracking platforms globally.[43] To maximize the effect of antibiotics, the prescriber should have a thorough knowledge of local microbiology and susceptibility patterns, bacterial status (inoculum size) along with site of infection, antimicrobial concentration and dosing required, minimum inhibitory concentration (MIC), mutant spectral window (MSW), mutant prevention concentration (MPC) and minimum bactericidal concentration (MBC).[44] The prescriber should assess the influence of host factors such as the volume of distribution, presence of hypoproteinemia and organ dysfunctions (renal/hepatic), while addressing pharmacological aspects (hydrophilic/lipophilic, molecular weight and protein binding) and type of killing properties (time dependent/concentration dependent; bacteriostatic/bactericidal) to decide appropriate dose and duration of therapy.[45] To tackle antibiotic resistance, every hospital should monitor quality indicators of stewardship program including structural (establishment of stewardship teams, computerized physician order entry), process (antibiotic time outs) and outcome (defined daily dose: DDD, duration of therapy: DOT) measures with frequent audits.[46,47]

**Conclusion**

Bacteria which have dominated ecological systems for millennia cannot be vanquished for good. Therefore, we conclude that new antibacterials cannot remain new or promising for long. Using existing antibacterials along with strong adherence to infection control practices and antimicrobial stewardship is the best option to redeem our species from the threat of AMR.
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Gould K. Antibiotics: From prehistory to the present day. J Antimicrob Chemother. 2016;71:572–5. [PubMed: 26851273]

2. Davies J. Where have all the antibiotics gone? Can J Infect Dis Med Microbiol. 2006;17:287–90. [PMCID: PMC2095086] [PubMed: 18382641]

3. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417–33. [PMCID: PMC2937522] [PubMed: 20805405]

4. Divatia J V, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S, et al. Intensive care in India: The indian intensive care case mix and practice patterns study. Indian J Crit Care Med. 2016;20:216–25. [PMCID: PMC4859158] [PubMed: 27186054]

5. Mascini EM, Bonten MJM. Vancomycin-resistant enterococci: Consequences for therapy and infection control. Clin Microbiol Infect. 2005;11:43–56. [PubMed: 15953021]

6. Cheesman MJ, Ilanko A, Blonk B, Cock IE. Developing new antimicrobial therapies: Are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution? Pharmacogn Rev. 2017;11:57–72. [PMCID: PMC5628525] [PubMed: 28989242]

7. Theuretzbacher U, Van Bambeke FV, Cantón R, Giske CG, Mouton JW, Nation RL, et al. Reviving old antibiotics. J Antimicrob Chemother. 2015;70:2177–81. [PubMed: 26063727]

8. Mashni O, Nazer L, Le J. Critical review of double-carbapenem therapy for the treatment of carbapenemase-producing klebsiella pneumoniae. Ann Pharmacother. 2019;53:70–81. [PubMed: 30019911]

9. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368:407–15. [PubMed: 23323867]

10. Vázquez R, García E, García P. Phage lysins for fighting bacterial respiratory infections: A new generation of antimicrobials. Front Immunol. 2018;9:2252. [PMCID: PMC6232686] [PubMed: 30459750]

11. Han JW, Choi GJ, Kim BS. Antimicrobial aromatic polyketides: A review of their antimicrobial properties and potential use in plant disease control. World J Microbiol Biotechnol. 2018;34:163. [PubMed: 30368604]

12. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: Present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227–49. [PMCID: PMC5317269] [PubMed: 28243086]

13. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–18. [PMCID: PMC4768623] [PubMed: 26343252]

14. Valeanu L, Stefan MG, Andrei S, Chirvasuta R. New FDA approved antibacterial drugs: 2015-2017. Discoveries. 2018;6:e81.
15. David MZ, Dryden M, Gottlieb T, Tattevin P, Gould IM. Recently approved antibacterials for methicillin-resistant *Staphylococcus aureus* (MRSA) and other Gram-positive pathogens: The shock of the new. Int J Antimicrob Agents. 2017;50:303–7. [PubMed: 28666751]

16. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–79. [PubMed: 24897082]

17. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, et al. CANVAS 1: The first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65:41–51. [PubMed: 21115454]

18. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66:53–9. [PubMed: 21482570]

19. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. JAMA. 2013;309:559. [PubMed: 23403680]

20. Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ. Delafloxacin: Place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7:197–217. [PMCID: PMC5986682] [PubMed: 29605887]

21. Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: A Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471–80. [PMCID: PMC5890686] [PubMed: 29029278]

22. Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Ph D, et al. Fidaxomicin versus vancomycin for. N Engl J Med. 2011;364:422–31. [PubMed: 21288078]

23. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for *clostridium difficile* infection in adults and children: 2017 Update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA) Clin Infect Dis. 2018;66:e1–48. [PMCID: PMC6018983] [PubMed: 29462280]

24. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for *clostridium difficile* infection. N Engl J Med. 2011;364:422–31. [PubMed: 21288078]

25. Wilcox MH, Gerding DN, Poxtton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent *Clostridium difficile* infection (MODIFY I and II trials) N Engl J Med. 2017;376:305–17. [PubMed: 28121498]

26. Karaiskos I, Galani I, Souli M, Giamarellou H. Novel β-lactam-β-lactamase inhibitor combinations: Expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15:133–49. [PubMed: 30626244]

27. Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;2(11):1219–36. [PubMed: 30444147]

28. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23:704–12. [PubMed: 28893690]
29. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/tazobactam plus metronidazole for complicating intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI) Clin Infect Dis. 2015;60:1462–71. [PMCID: PMC4412191] [PubMed: 25670823]

30. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI) Lancet. 2015;385:1949–56. [PubMed: 25931244]

31. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380–9. [PMCID: PMC4872289] [PubMed: 26962078]

32. Zhang Y, Tao L, Qu X, Niu J, Ding Y, Zhang S. Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials. Rev Assoc Med Bras. 2018;64:253–63. [PubMed: 29641778]

33. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95. [PubMed: 29254862]

34. Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection. JAMA. 2018;27:319–788. [PMCID: PMC5838656] [PubMed: 29486041]

35. Solano C, Echeverz M, Lasa I. Biofilm dispersion and quorum sensing. Curr Opin Microbiol. 2014;18:96–104. [PubMed: 24657330]

36. Sarma P, Mahendiratta S, Prakash A, Medhi B. Specifically targeted antimicrobial peptides: A new and promising avenue in selective antimicrobial therapy. Indian J Pharmacol. 2018;50:1–3. [PMCID: PMC5954627] [PubMed: 29861521]

37. Bierbaum G, Sahl HG. Lantibiotics: Mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol. 2009;10:2–18. [PubMed: 19149587]

38. Aoki W, Ueda M. Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals. 2013;6:1055–81. [PMCID: PMC3817730] [PubMed: 24276381]

39. Fischetti V. Development of phage lysins as novel therapeutics: A historical perspective. Viruses. 2018;10:E310. [PMCID: PMC6024357] [PubMed: 29875339]

40. Kollef MH. Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia. JAMA. 2008;300:805. [PubMed: 18714060]

41. Laupland KB, Fisman DN. New antibacterials? Can J Infect Dis Med Microbiol. 2010;21:71–3. [PMCID: PMC2912108] [PubMed: 21629613]

42. Rupali P, Palanikumar P, Shanthamurthy D, Peter JV, Kandasamy S, Zacchaeus NG, et al. Impact of an antimicrobial stewardship intervention in India: Evaluation of post-prescription review and feedback as a method of promoting optimal antimicrobial use in the intensive care units of a tertiary-care hospital. Infect Control Hosp Epidemiol. 2019;40:512–519. [PubMed: 31084674]
New and promising anti-bacterials: Can this promise be sustained?

43. Klein EY, Tseng KK, Pant S, Laxminarayan R. Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ Glob Health. 2019;4:e001315. [PMCID: PMC6509601] [PubMed: 31139449]

44. Li J, Xie S, Ahmed S, Wang F, Gu Y, Zhang C, et al. Antimicrobial activity and resistance: Influencing factors. Front Pharmacol. 2017;13:364. [PMCID: PMC5468421] [PubMed: 28659799]

45. Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol. 2010;23:472–8. [PubMed: 20489605]

46. Arcenillas P, Boix-Palop L, Gomez L, Xercavins M, March P, Martinez L, et al. Assessment of quality indicators for appropriate antibiotic use. Antimicrob Agents Chemother. 2018;26:62. [PMCID: PMC6256780] [PubMed: 30249698]

47. Singh R, Azim A, Gurjar M, Poddar B, Baronia AK. Audit of antibiotic practices: An experience from a tertiary referral center. Indian J Crit Care Med. 2019;23:7–10. [PMCID: PMC6481268] [PubMed: 31065201]

**Figures and Tables**
Figure 1

Time line of anti-bacterials discovery and development of resistance. Annexure to Figure 1 of new and promising anti-bacterials. PRSA = penicillin resistant Staphylococcus aureus; MRSA: methicillin resistant staphylococcus aureus; PRP = penicillin resistant pneumococcus; NRE = nalidixic acid resistant enterococci; GRE = gentamicin resistant enterococci; ESBL-E = ESBL producing Enterobacteriaceae; VRE = vancomycin resistant enterococci; LRP = Levofloxacin resistant pneumococcus; MBL = metallo β-lactamases; VRSA = vancomycin resistant staphylococcus aureus; CRSA = Ceftaroline resistant staphylococcus aureus; KPC = Klebsiella pneumoniae producing carbapenemases CRKP = Colistin resistant Klebsiella pneumoniae; CRIP = Ceftaroline resistant staphylococcus aureus
Table 1

Comparative table of new and promising antibacterials

| Name of the antibacterial | Oritavancin | Dalbavancin fosamil | Ceftaroline fosamil | Tedizolid | Delafloxacin | Fidaxomicin |
|---------------------------|-------------|---------------------|---------------------|-----------|--------------|-------------|
| Added antimicrobial spectrum | VRE (non-van A mediated) including Daptomycin resistant; MRSA (mec A and mec C); VRSA and some VISA/hVISA | MRSA E. faecalis | NIL | NIL | Narrowed spectrum t .difficile |
| PK/PD advantage | t1/2: >250 h | t1/2: >350 h | NIL | t1/2: 12 h → Once daily dosage | Weak acidic property (↑ intracellular penetration and active in acidic pH). Clearance by non-renal pathways |
| Dose | 1200 mg IV one dose | 1000 mg first dose followed by 500 mg on day 8 | 600 mg IV Q12H | 200 mg IV (lyophilized powder) or E/R for 6 days | 300 mg IV Q 12 h 450 mg E/R Q 12 h | 200 mg Q 12 h through route |
| Indications(FDA Approved) | ABSSI | ABSSI | ABSSI | ABSSI | ABSSI | CDI even episode an first recurrence Severe CD |
| Strengths | Long et1/2 No dose adjustments in renal and hepatic failure No TDM requirement | Activity against MRSA with increased binding to | ↓myelosuppression ↓MAO inhibition ↓peripheral and optic neuropathy ↓lactic acidosis Not inactivated by | Minimal QTc prolongation Very low frequency of spontaneous mutations Less | Minimal systemic absorption High fecal concentrat |

PK/PD=Pharmacokinetic and pharmacodynamic; FDA=Food and Drug administration; VRE=vancomycin resistant enterococci; MRSA=methicillin resistant staphylococcus aureus; VRSA=vancomycin resistant staphylococcus aureus; VISA=vancomycin intermediate staphylococcus aureus; hVISA=hetero-resistant staphylococcus aureus; E. faecalis=Enterococcus faecalis; E. faecium=Enterococcus faecium; ABSSI=acute bacterial skin and skin structure infection; TDM=therapeutic drug monitoring; et1/2=elimination half time; ESBL-E=ESBL producing Enterobacteriaceae; FQ=fluroquinolone; CDI=Clostridium difficile infection; CRPA=Carbapenem resistant
Pseudomonas aeruginosa; CRAB=Carbapenem resistant Acinetobacter baumannii; KPC=Klebsiella pneumoniae producing carbapenamases; IV=intravenous; E/R=enteral route; Q 12 h=every 12 hours; Q24 h=once in every 24 h; Q8 h=every 8 hours; c-IAI=complicated intraabdominal infection; c-UTI=complicated urinary tract infection; MBL=metallo β-lactamases; HAP=hospital acquired pneumonia; VAP=ventilator associated pneumonia; ↓ = decreased